ERBB2 and urinary bladder carcinoma: HER2 amplification is found in 15–20% of breast cancers1,2, and HER2 overexpression or activating mutations are clinically relevant in other solid tumours such as bladder cancer, gastric, colorectal, and lung adenocarcinoma3–5.